Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 11 |
| List of Tables | 10 | 2 |
| List of Figures | 12 | 1 |
| Introduction | 13 | 1 |
| Global Markets Direct Report Coverage | 13 | 1 |
| Acne Vulgaris Overview | 14 | 1 |
| Therapeutics Development | 15 | 2 |
| Pipeline Products for Acne Vulgaris Overview | 15 | 1 |
| Pipeline Products for Acne Vulgaris Comparative Analysis | 16 | 1 |
| Acne Vulgaris Therapeutics under Development by Companies | 17 | 3 |
| Acne Vulgaris Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Acne Vulgaris Pipeline Products Glance | 21 | 3 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Acne Vulgaris Products under Development by Companies | 24 | 4 |
| Acne Vulgaris Products under Investigation by Universities/Institutes | 28 | 1 |
| Acne Vulgaris Companies Involved in Therapeutics Development | 29 | 43 |
| 3SBio Inc. | 29 | 1 |
| Allergan Plc | 30 | 1 |
| Almirall, S.A. | 31 | 1 |
| Antibiotx ApS | 32 | 1 |
| Biomar Microbial Technologies | 33 | 1 |
| BiopharmX, Inc. | 34 | 1 |
| Braintree Laboratories, Inc. | 35 | 1 |
| Brickell Biotech, Inc. | 36 | 1 |
| Cell Medica Limited | 37 | 1 |
| Cellceutix Corporation | 38 | 1 |
| Celtaxsys, Inc. | 39 | 1 |
| Common Pharma Inc | 40 | 1 |
| Cutanea Life Sciences Inc | 41 | 1 |
| DermaXon, LLC | 42 | 1 |
| Dermira Inc. | 43 | 1 |
| Diffusion Pharmaceuticals Inc. | 44 | 1 |
| ELORAC, Inc. | 45 | 1 |
| Ensol Biosciences Inc. | 46 | 1 |
| Foamix Pharmaceuticals Ltd. | 47 | 1 |
| Galderma S.A. | 48 | 1 |
| GlaxoSmithKline Plc | 49 | 1 |
| Helix BioMedix, Inc. | 50 | 1 |
| Hovione FarmaCiencia SA | 51 | 1 |
| Lee's Pharmaceutical Holdings Limited | 52 | 1 |
| LEO Pharma A/S | 53 | 1 |
| Novabiotics Limited | 54 | 1 |
| Novan, Inc. | 55 | 1 |
| Paratek Pharmaceuticals, Inc. | 56 | 1 |
| Pfizer Inc. | 57 | 1 |
| Phosphagenics Limited | 58 | 1 |
| Photocure ASA | 59 | 1 |
| Promius Pharma, LLC | 60 | 1 |
| Provectus Biopharmaceuticals, Inc. | 61 | 1 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 62 | 1 |
| Sol-Gel Technologies Ltd. | 63 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 64 | 1 |
| Telesso Technologies Limited | 65 | 1 |
| Thesan Pharmaceuticals, Inc. | 66 | 1 |
| Valeant Pharmaceuticals International, Inc. | 67 | 1 |
| Vectura Group Plc | 68 | 1 |
| Vyome Biosciences Private Limited | 69 | 1 |
| XBiotech Inc | 70 | 1 |
| Xenon Pharmaceuticals Inc. | 71 | 1 |
| Acne Vulgaris Therapeutics Assessment | 72 | 12 |
| Assessment by Monotherapy Products | 72 | 1 |
| Assessment by Combination Products | 73 | 1 |
| Assessment by Target | 74 | 3 |
| Assessment by Mechanism of Action | 77 | 3 |
| Assessment by Route of Administration | 80 | 2 |
| Assessment by Molecule Type | 82 | 2 |
| Drug Profiles | 84 | 95 |
| (adapalene + clindamycin hydrochloride) Drug Profile | 84 | 1 |
| (benzoyl peroxide + tretinoin) Drug Profile | 85 | 1 |
| (clindamycin phosphate + tretinoin) Drug Profile | 86 | 1 |
| A-3APO Drug Profile | 87 | 1 |
| acebilustat Drug Profile | 88 | 3 |
| Aczone Combo Drug Profile | 91 | 1 |
| Aczone X Drug Profile | 92 | 1 |
| aminolevulinic acid hydrochloride Drug Profile | 93 | 1 |
| AQ-401 Drug Profile | 94 | 1 |
| ATx-202 Drug Profile | 95 | 1 |
| B-244 Drug Profile | 96 | 1 |
| BBI-3000 Drug Profile | 97 | 1 |
| benzoyl peroxide Drug Profile | 98 | 1 |
| BLI-1100 Drug Profile | 99 | 1 |
| botulinum toxinA Drug Profile | 100 | 1 |
| brilacidin tetrahydrochloride Drug Profile | 101 | 9 |
| CB-0301 Drug Profile | 110 | 3 |
| CB-0601 Drug Profile | 113 | 1 |
| CLS-007 Drug Profile | 114 | 1 |
| dapsone Drug Profile | 115 | 1 |
| DFD-10 Drug Profile | 116 | 1 |
| DLX-2323 Drug Profile | 117 | 1 |
| DLX-2681 Drug Profile | 118 | 1 |
| DMT-210 Drug Profile | 119 | 1 |
| DRM-01 Drug Profile | 120 | 3 |
| DX-0385 Drug Profile | 123 | 1 |
| E-10215 Drug Profile | 124 | 1 |
| finasteride Drug Profile | 125 | 1 |
| FMX-101 Drug Profile | 126 | 3 |
| GSK-1940029 Drug Profile | 129 | 1 |
| HB-1345 Drug Profile | 130 | 1 |
| Hesed-4000 Drug Profile | 131 | 1 |
| IB-07A037 Drug Profile | 132 | 1 |
| IDP-120 Drug Profile | 133 | 1 |
| IDP-121 Drug Profile | 134 | 1 |
| IDP-123 Drug Profile | 135 | 1 |
| IDP-126 Drug Profile | 136 | 1 |
| IDP-129 Drug Profile | 137 | 1 |
| IDP-130 Drug Profile | 138 | 1 |
| ivermectin Drug Profile | 139 | 1 |
| LEO-43204 Drug Profile | 140 | 1 |
| LTA-001 Drug Profile | 141 | 1 |
| methyl aminolevulinate hydrochloride Drug Profile | 142 | 2 |
| minocycline Drug Profile | 144 | 1 |
| minocycline Drug Profile | 145 | 2 |
| minocycline hydrochloride Drug Profile | 147 | 1 |
| MTC-896 Drug Profile | 148 | 1 |
| omiganan pentahydrochloride Drug Profile | 149 | 2 |
| Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer Drug Profile | 151 | 1 |
| PF-06423264 Drug Profile | 152 | 1 |
| PH-10 Drug Profile | 153 | 3 |
| RA-18C3 Drug Profile | 156 | 2 |
| RES-440 Drug Profile | 158 | 2 |
| sarecycline hydrochloride Drug Profile | 160 | 2 |
| SB-204 Drug Profile | 162 | 3 |
| SKP-026 Drug Profile | 165 | 1 |
| Small Molecule for Acne and Skin Inflammation Drug Profile | 166 | 1 |
| Small Molecules for Acne Vulgaris Drug Profile | 167 | 1 |
| Synthetic Peptide for Acne Vulgaris Drug Profile | 168 | 1 |
| Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke Drug Profile | 169 | 1 |
| tazarotene Drug Profile | 170 | 1 |
| tretinoin Drug Profile | 171 | 1 |
| tretinoin Drug Profile | 172 | 1 |
| trifarotene Drug Profile | 173 | 2 |
| TSN-2898 Drug Profile | 175 | 1 |
| Vaccine for Acne Vulgaris Drug Profile | 176 | 1 |
| VB-1953 Drug Profile | 177 | 1 |
| XEN-801 Drug Profile | 178 | 1 |
| Acne Vulgaris Dormant Projects | 179 | 7 |
| Acne Vulgaris Discontinued Products | 186 | 1 |
| Acne Vulgaris Product Development Milestones | 187 | 12 |
| Featured News &Press Releases | 187 | 1 |
| Sep 28, 2016: Novan Announces Both SB204 Phase 3 Pivotal Trials Fully Enrolled | 187 | 1 |
| Aug 24, 2016: BioPharmX Enrolls First Subject in OPAL Phase 2b Clinical Trial of BPX-01 Topical Minocycline for the Treatment of Acne | 187 | 1 |
| Aug 22, 2016: BioPharmX Announces Final Phase 2a Trial Results Find BPX-01 Reduces Facial P. Acnes by More than 90% in Four Weeks | 188 | 1 |
| Jul 21, 2016: BioPharmX Study Shows BPX-01 Topical Gel Delivers Minocycline Precisely to the Skin | 189 | 1 |
| Jun 29, 2016: BioPharmX Announces Positive Topline Phase 2a Clinical Trial Results for BPX-01 in Patients with Acne-Causing Bacteria | 190 | 1 |
| Jun 08, 2016: Xenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic XEN801 Program at the Jefferies 2016 Healthcare Conference | 191 | 1 |
| May 11, 2016: Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting | 192 | 1 |
| May 10, 2016: Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris | 192 | 2 |
| May 09, 2016: Foamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101 | 194 | 1 |
| Apr 25, 2016: BioPharmX Announces Full Patient Enrollment in Phase 2a Study of BPX-01 Topical Antibiotic for Acne | 195 | 1 |
| Mar 03, 2016: BioPharmX commences Phase 2 clinical study under U.S. FDA IND for BPX-01 | 195 | 1 |
| Mar 01, 2016: Novan Phase 2b Results with SB204 to be Presented at American Academy of Dermatology | 196 | 1 |
| Feb 23, 2016: Novan Announces First Patient Dosed in Phase 3 Program for SB204 | 196 | 1 |
| Feb 15, 2016: Visonac Data Were Presented at The Euro PDT Congress in Barcelona February 13th | 197 | 1 |
| Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne | 197 | 2 |
| Appendix | 199 | 2 |
| Methodology | 199 | 1 |
| Coverage | 199 | 1 |
| Secondary Research | 199 | 1 |
| Primary Research | 199 | 1 |
| Expert Panel Validation | 199 | 1 |
| Contact Us | 199 | 1 |
| Disclaimer | 200 | 1 |